Risk Factors for Developing Nonmelanoma Skin Cancer after Lung Transplantation

Table 1

Patient demographic characteristics.

		Quasi Intention to Trea			Quasi Per Protoco
	All Patients	Everolimus Arm	MMF Arm		Remained on Everolimus	Other Immunosuppression
Characteristi	(n=90)	(n=49)	(n=41)	P Value	(n=18)	(n=72)	P Value
Age, median (range), y	56 (28 – 71)	53 (28 – 67)	58 (29 – 71)	.0	58 (31 – 67)	53 (28 – 71)	.2
Sex, No. (%)
Female	41 (46)	24 (49)	17 (42)	.4	11 (61)	30 (42)	.1
Male	49 (54)	25 (51)	24 (59)		7 (39)	42 (58)
Follow-up, median (range), m	101 (69 – 128)	101 (69 – 126)	102 (73 – 128)	.5	103 (77 – 126)	101 (69 – 128)	.3
Fitzpatrick skin type, No. (%)
I	13 (14)	6 (12)	7 (17)	.2	1 (6)	12 (17)	.4
II	46 (51)	29 (59)	17 (42)		12 (67)	34 (47)
III	29 (32)	14 (29)	15 (37)		5 (28)	24 (33)
IV	2 (2)	0 (0)	2 (5)		0 (0)	2 (3)
Hair color, No. (%)
Red	7 (8)	3 (6)	4 (10)	.5	1 (6)	6 (8)	.6
Light blonde	11 (12)	8 (16)	3 (7)		3 (17)	8 (11)
Dark blonde	46 (51)	25 (51)	21 (51)		7 (39)	39 (54)
Brown	25 (28)	13 (27)	12 (29)		7 (39)	18 (25)
Black	1 (1)	0 (0)	1 (2)		0 (0)	1 (1)
History of pre-transplant cancer, No. (%)
Skin
Yes	1 (1)	0 (0)	1 (2)	.4	0 (0)	1 (1)	>.9
No	89 (99)	49 (100)	40 (98)		18 (100)	71 (99)
Other
Yes	2 (2)	1 (2)	1 (2)	>.9	0 (0)	2 (3)	>.9
No	88 (98)	48 (98)	40 (98)		18 (100)	70 (97)
Underlying disease, No. (%)
Cystic fibrosis	26 (29)	14 (29)	12 (29)	.2	2 (11)	24 (33)	.1
Emphysema	32 (36)	14 (29)	18 (44)		6 (33)	26 (36)
Pulmonary fibrosis	19 (21)	14 (29)	5 (12)		7 (39)	12 (17)
Other	13 (14)	7 (14)	6 (15)		3 (17)	10 (14)
Transplant type, No. (%)
Bilateral	84 (93)	45 (92)	39 (95)	.6	16 (89)	68 (94)	.6
Unilateral	6 (7)	4 (8)	2 (5)		2 (11)	4 (6)
Voriconazole exposure, No. (%)
Yes	40 (44)	22 (45)	18 (44)	.9	5 (28)	35 (49)	.1
No	50 (56)	27 (55)	23 (56)		13 (72)	37 (51)
>6 month	12 (13)	7 (14)	5 (12)	.7	2 (11)	10 (14)	>.9
≤6 month	78 (87)	42 (86)	36 (88)		16 (89)	62 (86)

MMF, mycophenolate mofetil.
Patients stratified by original therapy arms from the previous interventional trial “Immunosuppressive therapy with Certican® (Everolimus) after lung transplantation”.
Comparing patients from the former everolimus arm, who remained on everolimus until dermatologic exam to all other patients.
Percentages have been rounded to whole numbers and may not add up to 100.
Calculated using the Mann-Whitney-U test.
Calculated using the χ²-test.
Calculated using the Fisher exact test.
Calculated cumulating all periods of voriconazole intake.